Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL FRONTIERS - 58th Annual Scientific Session of the American College of Cardiology
Large Reductions in LDL-C Yield Major Reduction in Venous Thromboembolism: Secondary Data from JUPITER
Orlando, Florida / March 29-31, 2009
Orlando - Highly significant and substantial reductions in rates of venous thromboembolism (VTE) are produced by intensive lowering of LDL-C levels, according to a new set of data from a primary prevention study. The study recruited...
PRIORITY PRESS - 58th Annual Scientific Session of the American College of Cardiology
Proton Pump Inhibition and Antiplatelet Activity: A Question of Metabolic Pathways
Orlando, Florida / March 29-31, 2009
Orlando - The potential for proton pump inhibitors (PPIs) to diminish the antiplatelet effects of clopidogrel has been clarified by a series of recent studies, including two presented here at the 2009 ACC meeting. Consistent with known...
PHYSICIAN PERSPECTIVE Viewpoint based on presentations from the 58th Annual Scientific Session of the American College of Cardiology
Investigating Interaction Between Thienopyridine Antiplatelet Activity and Proton Pump Inhibition
Orlando, Florida / March 29-31, 2009
INTRODUCTION A series of recent studies have raised concern that proton pump inhibitors (PPIs), a drug class that inhibits gastric acid secretion, may impair the antiplatelet activity of clopidogrel. The potential for concern is raised...
JOURNAL CLUB 2009 - Cardiology
Results and Clinical Implications of JUPITER: A Quebec Perspective
March 2009
Editorial Overview: Jacques Genest, Jr., MD, FRCPC Professor of Medicine, McGill University Novartis Chair in Medicine, Montreal, Quebec Otherwise healthy older individuals without hyperlipidemia benefit from intensive reductions of LDL-C...
MEDICAL FRONTIERS - 34th International Stroke Conference
Primary Stroke Prevention: New Findings from JUPITER
San Diego, California / February 18-20, 2009
San Diego - In a major multinational trial, a statin has provided protection against stroke that approaches that observed against myocardial infarction (MI). Although previous studies have associated statins with a reduction in stroke risk,...
JOURNAL CLUB 2009 - Cardiology
The Clinical Impact of JUPITER
February 2009
Editorial Overview: Jacques Genest, Jr., MD, FRCPC Professor of Medicine, McGill University Montreal, Quebec A large multinational trial has confirmed the hypothesis that high-sensitivity C-reactive protein (hsCRP) can identify patients at...
JOURNAL CLUB 2008 - Cardiology
Cholesterol hypothesis and the effect of the SEAS study
December 2008
Editorial Overview: David Fitchett, MD, FRCPC Division of Cardiology, St. Michael’s Hospital, Associate Professor of Medicine, University of Toronto, Toronto, Ontario The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial tested a...
PHYSICIAN PERSPECTIVE Viewpoint based on the following article: Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes Sep 2008;32(suppl 1).
New Diabetes Guidelines Modify Recommendations for Vascular Protection
December 2008
INTRODUCTION Due to evidence that vascular protection improves the outcome in patients with diabetes mellitus, the Canadian Diabetes Association (CDA) has devoted a special section to this area of management in new guidelines. In this...
NEW FRONTIERS - 81st Scientific Sessions of the American Heart Association
Cardiovascular Risk Reduction – Clinical Impact of JUPITER
New Orleans, Louisiana / November 9-12, 2008
Intensive lipid-lowering in individuals selected primarily for their elevated high-sensitivity C-reactive Protein (hsCRP) levels has provided one of the largest relative reductions in cardiovascular (CV) risk ever recorded in a primary...